Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Shineway Pharmaceutical Group Limited ( (HK:2877) ) has shared an announcement.
China Shineway Pharmaceutical Group Limited reported a 20.8% decrease in turnover for the first half of 2025, with a slight decline in net profit by 1.9% due to industry-wide challenges such as shrinking demand and rising production costs. Despite these setbacks, the company managed to increase its net profit margin to 37.2% through cost control measures and increased investment income, while maintaining a stable cash flow.
The most recent analyst rating on (HK:2877) stock is a Buy with a HK$8.50 price target. To see the full list of analyst forecasts on China Shineway Pharmaceutical Group Limited stock, see the HK:2877 Stock Forecast page.
More about China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited operates in the traditional Chinese medicine (TCM) industry, focusing on producing and distributing TCM products. The company is involved in the healthcare sector, emphasizing cost control and efficiency amid industry challenges.
Average Trading Volume: 1,094,158
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$6.37B
See more insights into 2877 stock on TipRanks’ Stock Analysis page.